Literature DB >> 21148607

Antiglycine-receptor encephalomyelitis with rigidity.

Natalia Mas1, Albert Saiz, Maria Isabel Leite, Patrick Waters, Manuel Baron, Dolores Castaño, Lidia Sabater, Angela Vincent, Francesc Graus.   

Abstract

BACKGROUND: Glycine receptor antibodies (GlyR-ab) were reported in a patient with progressive encephalomyelitis with rigidity and myoclonus (PERM).
METHODS: Three additional patients were clinically described. GlyR-ab was detected with a cell-based assay of HEK293 cells transfected with the α1 subunit of the GyR.
RESULTS: A 33-year-old woman presented with diplopia, dysphagia and gait ataxia that improved in 5 weeks. Then, she developed a typical stiff-person syndrome (SPS) that resolved with corticosteroids, but relapsed 17 months later with a stiff limb syndrome. After treatment with intravenous immunoglobulins (IVIG), she has been asymptomatic for 8 years. A 60-year-old man developed, dysphagia, diplopia, left facial palsy and right trigeminal hypoaesthesia in a few days, followed by muscular rigidity, corticospinal signs, myoclonic jerks and severe dysautonomia. He developed seizures and suffered a cardiac arrest that left him in a persistent vegetative state. A 48-year-old man presented with leg rigidity and frequent spells of trismus, muscle spasms followed by opisthotonus and diaphoresis. The symptoms were antedated by pruritus of the left scapulae, right arm and T11-T12 dermatome. At the same time he became progressively more aggressive with emotional irritability. He also developed dysgeusia (metallic taste) and severe concurrent behavioural changes and diurnal hypersomnia. Only the rigidity and the spasms improved after therapy.
CONCLUSIONS: The clinical picture associated with GlyR-ab is wider than the classical view of PERM. GlyR-ab should be examined in patients with core symptoms of muscle rigidity and spasms atypical for SPS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21148607     DOI: 10.1136/jnnp.2010.229104

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  42 in total

Review 1.  Neuronal surface antibody-mediated autoimmune encephalitis.

Authors:  Jenny J Linnoila; Myrna R Rosenfeld; Josep Dalmau
Journal:  Semin Neurol       Date:  2014-11-04       Impact factor: 3.420

Review 2.  Immune mediated diseases and immune modulation in the neurocritical care unit.

Authors:  Gloria von Geldern; Thomas McPharlin; Kyra Becker
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

Review 3.  Neuronal central nervous system syndromes probably mediated by autoantibodies.

Authors:  Aude Chefdeville; Jérôme Honnorat; Christiane S Hampe; Virginie Desestret
Journal:  Eur J Neurosci       Date:  2016-03-28       Impact factor: 3.386

Review 4.  [Antibody-associated diseases of the gray matter of the CNS: diagnosis and treatment].

Authors:  C G Bien
Journal:  Nervenarzt       Date:  2011-08       Impact factor: 1.214

5.  Paraneoplastic neurological syndromes: general treatment overview.

Authors:  Aurélien Viaccoz; Jérôme Honnorat
Journal:  Curr Treat Options Neurol       Date:  2013-04       Impact factor: 3.598

Review 6.  Autoantibodies to Synaptic Receptors and Neuronal Cell Surface Proteins in Autoimmune Diseases of the Central Nervous System.

Authors:  Josep Dalmau; Christian Geis; Francesc Graus
Journal:  Physiol Rev       Date:  2017-04       Impact factor: 37.312

Review 7.  Autoimmune encephalitis update.

Authors:  Josep Dalmau; Myrna R Rosenfeld
Journal:  Neuro Oncol       Date:  2014-03-16       Impact factor: 12.300

Review 8.  Autoimmune encephalopathies.

Authors:  Frank Leypoldt; Thaís Armangue; Josep Dalmau
Journal:  Ann N Y Acad Sci       Date:  2014-10-14       Impact factor: 5.691

Review 9.  Movement disorders in paraneoplastic and autoimmune disease.

Authors:  Jessica Panzer; Josep Dalmau
Journal:  Curr Opin Neurol       Date:  2011-08       Impact factor: 5.710

10.  Cerebellar ataxia and glutamic acid decarboxylase antibodies: immunologic profile and long-term effect of immunotherapy.

Authors:  Helena Ariño; Nuria Gresa-Arribas; Yolanda Blanco; Eugenia Martínez-Hernández; Lidia Sabater; Mar Petit-Pedrol; Idoia Rouco; Luis Bataller; Josep O Dalmau; Albert Saiz; Francesc Graus
Journal:  JAMA Neurol       Date:  2014-08       Impact factor: 18.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.